Northwest Biotherapeutics, Inc. is a development-stage biotechnology company engaging in the discovery, development and commercialization of immunotherapy products for treating cancers. The company’s DCVax uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company also develops DCVax-L, which is under Phase III clinical trials for glioblastoma multiforme brain cancer and ovarian cancer. For more information, visit the company’s website at www.nwbio.com.